PUBLISHER: DelveInsight | PRODUCT CODE: 1525037
PUBLISHER: DelveInsight | PRODUCT CODE: 1525037
DelveInsight's, "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Janus Kinase (JAK) Inhibitor: Understanding
Janus Kinase (JAK) Inhibitor: Overview
Janus kinase (JAK) inhibitors are small molecules approximately 400 Da that could be administrated as oral medicines. JAKs are phosphotransferases that bind to the intracellular domains of cytokine receptors and transmit signals to activate immune responses. The family of cytokines that signal via JAKs includes many interleukins, interferons, colony stimulating factors and hormonelike cytokines (such as erythropoietin). The receptors for these cytokines signal via various combinations of four JAKs (JAK1, JAK2, JAK3 and TYK2). First-generation jakinibs, such as tofacitinib and baricitinib (and oclacitinib in dogs), block more than one JAK, and thereby can inhibit a large number of cytokines; these and other pan-jakinibs are being investigated as therapeutic agents for a wide variety of autoimmune diseases.
JAK-STAT pathways are utilised by type I and II cytokine receptors, as well as by receptors for interferons and growth factors. These receptors lack intrinsic catalytic activity and rely on JAKs for downstream responses and subsequent modulation of gene expression Janus is the Greek god of doorways, looking both outside and inside a room, and illustrates how JAKs facilitate signals from the cell surface into the cell. Each cytokine receptor is paired with a different JAK pair, usually as heterodimers.
Upon cross-linking by its cytokine, the receptor-associated JAKs transphosphorylate one another. The activated JAKs in turn phosphorylate the cytokine receptor tail. The phosphorylated receptor forms a docking site for STATs, that otherwise reside in the cytosol. These STATs are then phosphorylated by the JAKs before dissociating from the receptor and themselves forming heterodimers or homodimers. They then translocate to the nucleus where they act as transcription factors, regulating gene expression. There are seven mammalian STATS which, like JAKs, associate with different signaling pathways.
Dysregulation of Jak catalytic activity can manifest as either a reduction or an increase in kinase activity, and is observed in pathogeneses including immunodeficiency, inflammatory diseases, hematological defects, autoimmune and myeloproliferative disorders, and susceptibility to infection. Altered Jak regulation occurs by multiple mechanisms, including: gene translocations, somatic or inherited point mutations, receptor mutations, and alterations in the activity of Jak regulators such as SOCS or phosphatases. The development of kinase inhibitors has offered new therapies for diverse clinical entities ranging from malignancy to autoimmunity. Jak inhibitors or Jakinibs initially launched to treat a rare hematologic disorder are now progressing to be used in not only malignancies but common autoimmune disorders as well.
The linkage of these pathologies with altered Jak catalytic activity has increased interest in development of Jak-specific inhibitors to treat classical myeloproliferative disorders and cancers, or to be used as immunosuppressant. Structural biology plays an important role in rational inhibitor design, and consequently, over the last few years crystal structures for all of the enzymatically active Jak kinase domains have been determined in complex with various ATP-competitive inhibitors.
"Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2024" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Janus Kinase (JAK) Inhibitor pipeline landscape is provided which includes the disease overview and Janus Kinase (JAK) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Janus Kinase (JAK) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Janus Kinase (JAK) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Janus Kinase (JAK) Inhibitor Emerging Drugs Chapters
This segment of the Janus Kinase (JAK) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Janus Kinase (JAK) Inhibitor Emerging Drugs
Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.
CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.
ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.
SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.
Further product details are provided in the report........
Janus Kinase (JAK) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Janus Kinase (JAK) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
DelveInsight's report covers around 55+ products under different phases of clinical development like
Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Janus Kinase (JAK) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Janus Kinase (JAK) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Janus Kinase (JAK) Inhibitor drugs.
Current Treatment Scenario and Emerging Therapies:
Key Players
Key Products
Introduction
Executive Summary
Janus Kinase (JAK) Inhibitor: Overview
Pipeline Therapeutics
Therapeutic Assessment
Janus Kinase (JAK) Inhibitor- DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Povorcitinib: Incyte Corporation
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
CPL409116: Celon Pharma
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
ATI-2138: Aclaris Therapeutics
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
SDC 1802: Sareum
Drug profiles in the detailed report.....
Inactive Products
Janus Kinase (JAK) Inhibitor Key Companies
Janus Kinase (JAK) Inhibitor Key Products
Janus Kinase (JAK) Inhibitor- Unmet Needs
Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
Janus Kinase (JAK) Inhibitor Analyst Views
Janus Kinase (JAK) Inhibitor Key Companies